Chemomab Therapeutics Ltd. and Scipher Medicine Corporation have entered into an all-stock merger agreement to create a Nasdaq-listed precision immunology company focused initially on nebokitug, a first-in-class anti-CCL24 antibody planned for a Phase 2 rheumatoid arthritis trial. The combined company is expected to operate as Scipher Medicine Corporation and trade under the ticker symbol SCIP,
MAIA Biotechnology has reported positive initial efficacy data from Part C of the Phase 2 THIO-101 expansion trial evaluating ateganosine followed by cemiplimab in third-line advanced non-small cell lung cancer. The clinical-stage oncology drug developer said the regimen produced a 90.5 percent interim disease control rate among efficacy-evaluable patients, placing its telomere-targeting strategy back in
Explore how Turn Therapeutics is refining the GX-03 Phase 2 trial after rapid eczema responses and a strong vehicle effect. Read what comes next.
Find out how Optimi Health’s UK psilocybin export could reshape psychedelic trial supply and what risks remain for Phase 2 research.
Genentech advances enicepatide and petrelintide obesity data at ADA 2026. Find out why Roche’s strategy matters now.
Ono’s ONO-2808 data hints at disease modification in MSA. See why Phase 3 may decide whether the signal becomes a breakthrough.
Can AIM ImmunoTech Inc.’s Ampligen improve checkpoint inhibitor responses in ovarian cancer? Explore the Phase 2 findings and implications.
A failed ALS endpoint meets a striking survival signal. Corcept now faces the harder test: proving dazucorilant in Phase 3.
Vyome’s VT-1953 shows strong Phase 2 results in cancer wound care. Find out how this breakthrough could reshape supportive oncology treatment today.
AN2 Therapeutics plans a Phase 2 trial of epetraborole for polycythemia vera. Explore what this strategy could mean for future hematology treatments.